Catalyst Dossier · compiled by CeliA 🧫

Recursion Pharmaceuticals, Inc. (RXRX)

Biological Products, (No Diagnostic Substances) · market cap $544M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-07-15 (est.)Phase 2 · REC-4881imp 7/10
2026-08-04Earningsimp 5/10
2027-01-15 (est.)Phase 2 · REC-4881imp 7/10
2027-06-15 (est.)Phase 2 · REC-4881imp 7/10

Pipeline

Asset	Phase	Indication
GTAEXS617	Phase 2	Advanced Solid Tumor
REC-4881	Phase 2	AXIN1 Gene Mutation
REC-994	Phase 2	Cerebral Cavernous Malformation
REC-1245	Phase 2	Unresectable

Price & technical context

3-month

+24.2%

6-month

-7.5%

12-month

-25.9%

52-wk range

$2.84–$6.79

vs 50-day MA

+14.4%

vs 200-day MA

-7.3%

Realized vol

70.0%

Max drawdown

-73.9%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for RXRX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.